Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Botaretigene sparoparvovec (Primary) ; Botaretigene sparoparvovec (Primary)
- Indications Retinitis pigmentosa
- Focus Registrational; Therapeutic Use
- Acronyms LUMEOS
- Sponsors Janssen-Cilag; MeiraGTx
- 28 Jun 2024 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 29 Jan 2024 Planned End Date changed from 19 Feb 2025 to 20 Sep 2024.
- 23 Jan 2024 Status changed from recruiting to active, no longer recruiting.